financetom
Business
financetom
/
Business
/
HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead
Oct 31, 2025 5:08 AM

NEW YORK and VIENNA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. ( HOOK ) today announced the completion of the sale of its assets related to HOOKIPA’s HB-400 program and certain of its assets related to HOOKIPA’s HB-500 program to Gilead Sciences, Inc. (“Gilead”).

In connection with the consideration and evaluation of HOOKIPA’s long-term prospects and strategies by HOOKIPA’s board of directors, on May 21, 2025 HOOKIPA entered into an asset purchase agreement (“Asset Purchase Agreement”) with Gilead pursuant to which Gilead agreed to acquire all of HOOKIPA’s assets primarily related to or necessary for the conduct of HOOKIPA’s HB-400 program, currently in clinical development for the treatment of hepatitis B virus, and certain of HOOKIPA’s assets related to HOOKIPA’s HB-500 program, currently in clinical development for the treatment of human immunodeficiency virus. HOOKIPA has been developing the HB-400 and HB-500 programs in collaboration with Gilead pursuant to the collaboration and license agreement with Gilead. The closing of the Asset Purchase Agreement occurred on October 30, 2025.

Availability of Other Information About HOOKIPA

Investors and others should note that we announce material financial information to our investors using our investor relations website, www.ir.hookipapharma.com, OTC Markets filings, press releases, public conference calls and webcasts. We use these channels, as well as social media, to communicate with our investors and the public about our company, and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on the social media channels listed on our investor relations website.

For further information, please contact:

Investors:

[email protected]

Image: https://www.globenewswire.com/newsroom/ti?nf=OTU2NTgwOSM3MjM1NjczIzIxNTY5MjI=

Image: https://ml.globenewswire.com/media/NTA4MzliNGYtY2Y0My00NThjLWIyODUtOGJhZDBmMzQxZDNhLTExNjg0OTMtMjAyNS0xMC0zMS1lbg==/tiny/HOOKIPA-Pharma-Inc.png Image: Primary Logo

Source: HOOKIPA Pharma Inc. ( HOOK )

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: Teradyne Shares Fall After Q2 Results, Q3 Outlook
Update: Teradyne Shares Fall After Q2 Results, Q3 Outlook
Jul 25, 2024
12:04 PM EDT, 07/25/2024 (MT Newswires) -- (Updates with latest stock move in the headline and first paragraph.) Teradyne ( TER ) shares fell almost 12% in recent Thursday trading after the company reported results for Q2 and provided guidance for Q3. The company reported Q2 non-GAAP earnings late Wednesday of $0.86 per diluted share, up from $0.79 per share...
Hermes 2Q sales rise 13% on continued appetite for high-end luxury
Hermes 2Q sales rise 13% on continued appetite for high-end luxury
Jul 25, 2024
PARIS (Reuters) -Birkin-bag maker Hermes reported a 13% rise in second-quarter sales on Thursday, demonstrating the continued appetite from wealthy shoppers for its luxury handbags, even as less affluent consumers pull back. Sales at the French luxury group grew to 3.7 billion euros ($4.02 billion), a 13% organic sales rise that strips out currency fluctuations. The figure was in line...
Update: Carpenter Technology Fiscal Q4 Tops Estimates; Shares Jump
Update: Carpenter Technology Fiscal Q4 Tops Estimates; Shares Jump
Jul 25, 2024
12:05 PM EDT, 07/25/2024 (MT Newswires) -- (Updates with stock price movement in the headline and first paragraph.) Carpenter Technology ( CRS ) shares were up over 14% in recent Thursday trading after the company posted fiscal Q4 earnings and revenue ahead of consensus. The company reported fiscal Q4 adjusted earnings of $1.82 per diluted share, up from $0.78 a...
Update: STMicroelectronics Shares Fall After Fiscal Q2 Earnings, Revenue Decline; Fiscal Q3 Revenue Outlook Issued
Update: STMicroelectronics Shares Fall After Fiscal Q2 Earnings, Revenue Decline; Fiscal Q3 Revenue Outlook Issued
Jul 25, 2024
12:05 PM EDT, 07/25/2024 (MT Newswires) -- (Updates with stock movement in the headline and first paragraph.) STMicroelectronics ( STM ) shares were down nearly 12% in recent Thursday trading after the company reported a year-over-year drop in its fiscal Q2 earnings. The company booked fiscal Q2 earnings of $0.38 per diluted share -- down from $1.06 a year earlier....
Copyright 2023-2026 - www.financetom.com All Rights Reserved